Expert Recap

Chronic Myeloid Leukemia

Source: Chronic Myeloid Leukemia*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Chronic Myeloid Leukemia

CME Program Director: Roy A. Beveridge, MD

Faculty:
Moshe Talpaz, MD

CME CREDIT INFORMATION

Release Date: 02/26/08

Expiration Date: 02/25/09

Physicians: maximum of 0.75 AMA PRA Category 1 Credit(s)™

Registered Nurses: 0.7 Nursing CE credit

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Describe the results of recent studies on the use of tyrosine kinase inhibitors in chronic myeloid leukemia
Discuss new insights into treatment options for patients who develop resistance to standard tyrosine kinase inhibitor treatment for chronic myeloid leukemia
Summarize how new developments in the analysis of BCR-ABL mutational status may impact treatment of chronic myeloid leukemia

CCO Expert Recaps combine slides with audio commentary by our esteemed faculty. Complete the CME posttest and evaluation after watching the presentation.

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.